Developer docs
API playgroundTry for free, no card

Search company profiles

Caregen Co. Ltd

Full company profile

uuid00433yx

Namestring
Caregen Co. Ltd
Legal namestring
Caregen Co. Ltd
Websiteurl
caregen.com
Company typeenum
Public
Founded yearint
2001
Descriptiontext

Caregen Co. Ltd is a South Korean KOSDAQ-listed biotechnology company founded in 2001 that develops, manufactures, and commercializes biomimetic (biologically inspired) peptide-based solutions across four product verticals: functional food supplements targeting metabolic health, body fat, blood sugar/cholesterol, and sarcopenia; Class III CE-certified medical devices including dermal fillers, hair fillers, body fillers, and arthritis injectables for the medical aesthetic market; cosmeceuticals covering skin, scalp, hair, and inner beauty; and pharmaceuticals, most notably CG-P5, a peptide eye-drop treatment for macular degeneration that has completed US FDA Phase 1 clinical trials, and CG-T1 for dry eye disease with additional trials planned. The company operates from five physical sites in Korea — a Seoul headquarters, an Anyang-si peptide R&D center and Creative Village, a Gunpo-si Cosmetic Research Institute and Factory 1, and a Hwaseong-si Peptide Foundry — providing vertical integration from peptide discovery through manufacturing.

The core of the business is a single biomimetic peptide technology platform that Caregen applies through multiple delivery formats and application designs rather than running separate R&D programs per vertical. This horizontal platform structure is intended to allow the same mechanistic peptide insights to inform ingredients, medical devices, cosmeceuticals, and ophthalmic drug candidates. Caregen monetizes the platform through direct sales of finished products, global distribution partner networks, and licensing programs targeting food supplements, medical devices, cosmeceuticals, and pharmaceutical applications. The company's go-to-market combines B2B distribution partnerships, presence at major international exhibitions across health, medical, beauty, and pharmaceutical sectors, and organic social channels (Instagram, Facebook, YouTube, Naver blog) for brand presence.

Revenue is generated across hardware sales (food supplements, medical devices, cosmeceuticals) and licensing/royalty streams (pharmaceutical assets and platform licensing). Specific pricing, contract structures, and revenue figures are not publicly disclosed. Customers are not named in the available data, and the company sells into B2B distribution partners and licensing counterparties rather than directly identified end accounts. No acquisitions, fundraising rounds, or leadership changes are disclosed in the source material, and Caregen appears to operate as an independent, publicly traded Korean biotech with no identified parent company.

Short descriptiontext

Caregen Co. Ltd is a South Korean KOSDAQ-listed biotech founded in 2001 that develops and commercializes biomimetic peptide-based products across functional food supplements, Class III medical devices, cosmeceuticals, and ophthalmic pharmaceuticals, serving global B2B distribution partners and licensing counterparties through a single integrated peptide platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomimetic peptide technology, cosmeceutical peptide ingredients, functional food supplements, medical device manufacturing, peptide drug development
Industry5 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYAFAJAKAG
Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYAFAJAHAI
Protein Hydrolysates & Peptides (Enzymatic Hydrolysates, Bioactive Peptides)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biotechnology — Biomimetic Peptide Ingredients and Products
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Functional Food Supplements
TypeHardware Sales
Description

Peptide-based functional healthcare solutions for metabolic health, body fat management, blood sugar-cholesterol management, and sarcopenia response across life care segments.

caregenglobal.imweb.me
2Medical Devices
TypeHardware Sales
Description

Class III medical devices including dermal fillers, hair fillers, body fillers for medical aesthetic markets, and arthritis injectables utilizing biomimetic peptide technology.

caregenglobal.imweb.me
3Cosmeceuticals
TypeHardware Sales
Description

Functional peptide-based solutions covering skin, scalp, hair, and inner beauty categories with integrated beauty solutions.

caregenglobal.imweb.me
4Pharmaceuticals - Licensing
TypeLicensing Royalties
Description

Peptide drug development including CG-P5 for macular degeneration (FDA Phase 1 completed) and CG-T1 for dry eye, targeting non-injection user-friendly treatments with potential licensing revenue.

caregenglobal.imweb.me
5Partnership & Licensing
TypeLicensing Royalties
Description

Global partnership and licensing programs for peptide platform technology and applications across food supplements, medical devices, cosmeceuticals, and pharmaceuticals sectors.

caregenglobal.imweb.me
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Caregen researches biological signaling mechanisms and develops biomimetic peptide-based solutions applied across four product categories: functional food supplements for metabolic health and body composition, Class III medical devices (dermal fillers, hair fillers, body fillers, and arthritis injectables), cosmeceuticals for skin, scalp, hair, and inner beauty, and peptide pharmaceuticals (CG-P5 for macular degeneration in eye drop form and CG-T1 for dry eye disease). The company operates its own peptide R&D centers and a dedicated Peptide Foundry for high-purity peptide manufacturing, and commercializes its platform through global distribution networks and partnership and licensing programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CG-P5 FDA Phase 1 clinical trial completed for macular degeneration treatment
+2 more records
Product overview1 text field

Caregen Co. Ltd operates as a biopharmaceutical company built around a single unified peptide technology platform that drives multiple product lines. The core platform consists of biomimetic peptide research and development capabilities, which Caregen applies across four distinct business segments: functional food supplements (metabolic health and body fat management), medical devices (Class III CE-certified dermal fillers, hair fillers, body fillers, and arthritis injections), cosmeceuticals (skin, scalp, and inner beauty solutions), and pharmaceuticals (CG-P5 for macular degeneration with FDA Phase 1 completion as an eye drop formulation, and CG-T1 for dry eye disease). The pharmaceutical products represent user-friendly, non-injection alternatives developed through the same peptide technology foundation.

Product and service8 records
1CG-P5 Macular Degeneration Treatment
CategoryPharmaceuticals — Ophthalmic Peptide Drug
Description

Peptide-based ophthalmic drug candidate for macular degeneration formulated as an eye drop (rather than an intravitreal injection), with US FDA Phase 1 clinical trial completed; targeted at pharmaceutical partners and ultimately patients with macular degeneration.

2CG-T1 Dry Eye Treatment
CategoryPharmaceuticals — Ophthalmic Peptide Drug
Description

Peptide-based therapeutic for dry eye disease, in development with additional clinical trials planned; targets pharmaceutical partners pursuing patient-friendly, non-injection ophthalmic treatments.

3Dermal Fillers (더말필러)
CategoryMedical Device — Class III Aesthetic Injectable
Description

Class III peptide-combination dermal filler medical device, CE certified under European standards, sold into the medical aesthetic market for facial volume and wrinkle indications.

4Hair Fillers (헤어필러)
CategoryMedical Device — Class III Aesthetic Injectable
Description

Class III peptide-based hair filler medical device for hair restoration and scalp treatment applications, CE certified and sold into the medical aesthetic market.

5Body Fillers (바디필러)
CategoryMedical Device — Class III Aesthetic Injectable
Description

Class III biomimetic peptide body filler medical device for body contouring and aesthetic treatments, positioned within the medical aesthetic device market.

6Arthritis Injection (관절염 주사제)
CategoryMedical Device — Therapeutic Injectable
Description

Peptide-based injectable medical device for arthritis treatment, used to expand Caregen's biomimetic peptide technology into the orthopedic and therapeutic medical device market.

7Functional Food Supplements
CategoryFunctional Food and Dietary Supplement Ingredients
Description

Peptide-based functional food and dietary supplement product line covering metabolic health, body fat management, blood sugar and cholesterol management, and sarcopenia response, sold to functional food brands and manufacturers as ingredients or finished products.

8Cosmeceutical Solutions
CategoryCosmeceutical — Functional Peptide Skincare, Haircare and Beauty Supplements
Description

Integrated peptide-based cosmeceutical product line covering skin care, scalp care, hair care, and inner beauty applications, supplied to cosmetic and personal care brands and distribution partners globally.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Global Distribution Partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Caregen operates global distribution networks to deliver its peptide-based solutions across food supplements, medical devices, cosmeceuticals, and pharmaceuticals to international markets. The company connects its technology and products directly to global markets through these distribution partnerships.

caregenglobal.imweb.me
2Partnership and Licensing Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Caregen offers partnership and licensing programs covering overview, types, value propositions, and global distribution aspects. Partners can access Caregen's peptide platform technology for applications in health functional foods, medical devices, cosmeceuticals, and pharmaceutical development including drug candidates like CG-P5.

caregenglobal.imweb.me
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Caregen Co. Ltd

Biotechnology — Biomimetic Peptide Ingredients and Productscaregen.com

Caregen Co. Ltd is a South Korean KOSDAQ-listed biotech founded in 2001 that develops and commercializes biomimetic peptide-based products across functional food supplements, Class III medical devices, cosmeceuticals, and ophthalmic pharmaceuticals, serving global B2B distribution partners and licensing counterparties through a single integrated peptide platform.

What Caregen Co. Ltd does

Caregen Co. Ltd is a South Korean KOSDAQ-listed biotechnology company founded in 2001 that develops, manufactures, and commercializes biomimetic (biologically inspired) peptide-based solutions across four product verticals: functional food supplements targeting metabolic health, body fat, blood sugar/cholesterol, and sarcopenia; Class III CE-certified medical devices including dermal fillers, hair fillers, body fillers, and arthritis injectables for the medical aesthetic market; cosmeceuticals covering skin, scalp, hair, and inner beauty; and pharmaceuticals, most notably CG-P5, a peptide eye-drop treatment for macular degeneration that has completed US FDA Phase 1 clinical trials, and CG-T1 for dry eye disease with additional trials planned. The company operates from five physical sites in Korea — a Seoul headquarters, an Anyang-si peptide R&D center and Creative Village, a Gunpo-si Cosmetic Research Institute and Factory 1, and a Hwaseong-si Peptide Foundry — providing vertical integration from peptide discovery through manufacturing.

The core of the business is a single biomimetic peptide technology platform that Caregen applies through multiple delivery formats and application designs rather than running separate R&D programs per vertical. This horizontal platform structure is intended to allow the same mechanistic peptide insights to inform ingredients, medical devices, cosmeceuticals, and ophthalmic drug candidates. Caregen monetizes the platform through direct sales of finished products, global distribution partner networks, and licensing programs targeting food supplements, medical devices, cosmeceuticals, and pharmaceutical applications. The company's go-to-market combines B2B distribution partnerships, presence at major international exhibitions across health, medical, beauty, and pharmaceutical sectors, and organic social channels (Instagram, Facebook, YouTube, Naver blog) for brand presence.

Revenue is generated across hardware sales (food supplements, medical devices, cosmeceuticals) and licensing/royalty streams (pharmaceutical assets and platform licensing). Specific pricing, contract structures, and revenue figures are not publicly disclosed. Customers are not named in the available data, and the company sells into B2B distribution partners and licensing counterparties rather than directly identified end accounts. No acquisitions, fundraising rounds, or leadership changes are disclosed in the source material, and Caregen appears to operate as an independent, publicly traded Korean biotech with no identified parent company.

Caregen Co. Ltd firmographics

Firmographics
Name
Caregen Co. Ltd
Legal name
Caregen Co. Ltd
Website
https://caregen.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
Caregen Co. Ltd is a South Korean KOSDAQ-listed biotech founded in 2001 that develops and commercializes biomimetic peptide-based products across functional food supplements, Class III medical devices, cosmeceuticals, and ophthalmic pharmaceuticals, serving global B2B distribution partners and licensing counterparties through a single integrated peptide platform.
Ownership category
akta.pro rank

Caregen Co. Ltd industry classification

Industry
Product category
Biotechnology — Biomimetic Peptide Ingredients and Products
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYAFAJAKAG
Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYAFAJAHAI
Protein Hydrolysates & Peptides (Enzymatic Hydrolysates, Bioactive Peptides)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • Biomimetic peptide technology
  • Cosmeceutical peptide ingredients
  • Functional food supplements
  • Medical device manufacturing
  • Peptide drug development

Where Caregen Co. Ltd is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Caregen Co. Ltd business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Functional Food Supplements: Peptide-based functional healthcare solutions for metabolic health, body fat management, blood sugar-cholesterol management, and sarcopenia response across life care segments.
  2. Medical Devices: Class III medical devices including dermal fillers, hair fillers, body fillers for medical aesthetic markets, and arthritis injectables utilizing biomimetic peptide technology.
  3. Cosmeceuticals: Functional peptide-based solutions covering skin, scalp, hair, and inner beauty categories with integrated beauty solutions.
  4. Pharmaceuticals - Licensing: Peptide drug development including CG-P5 for macular degeneration (FDA Phase 1 completed) and CG-T1 for dry eye, targeting non-injection user-friendly treatments with potential licensing revenue.
  5. Partnership & Licensing: Global partnership and licensing programs for peptide platform technology and applications across food supplements, medical devices, cosmeceuticals, and pharmaceuticals sectors.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Caregen Co. Ltd product offering

Product offering

Core offering

Caregen researches biological signaling mechanisms and develops biomimetic peptide-based solutions applied across four product categories: functional food supplements for metabolic health and body composition, Class III medical devices (dermal fillers, hair fillers, body fillers, and arthritis injectables), cosmeceuticals for skin, scalp, hair, and inner beauty, and peptide pharmaceuticals (CG-P5 for macular degeneration in eye drop form and CG-T1 for dry eye disease). The company operates its own peptide R&D centers and a dedicated Peptide Foundry for high-purity peptide manufacturing, and commercializes its platform through global distribution networks and partnership and licensing programs.

Product overview

Caregen Co. Ltd operates as a biopharmaceutical company built around a single unified peptide technology platform that drives multiple product lines. The core platform consists of biomimetic peptide research and development capabilities, which Caregen applies across four distinct business segments: functional food supplements (metabolic health and body fat management), medical devices (Class III CE-certified dermal fillers, hair fillers, body fillers, and arthritis injections), cosmeceuticals (skin, scalp, and inner beauty solutions), and pharmaceuticals (CG-P5 for macular degeneration with FDA Phase 1 completion as an eye drop formulation, and CG-T1 for dry eye disease). The pharmaceutical products represent user-friendly, non-injection alternatives developed through the same peptide technology foundation.

Differentiator

Problem solved

Functional benefit

Products and services

  • CG-P5 Macular Degeneration Treatment Peptide-based ophthalmic drug candidate for macular degeneration formulated as an eye drop (rather than an intravitreal injection), with US FDA Phase 1 clinical trial completed; targeted at pharmaceutical partners and ultimately patients with macular degeneration.
  • CG-T1 Dry Eye Treatment Peptide-based therapeutic for dry eye disease, in development with additional clinical trials planned; targets pharmaceutical partners pursuing patient-friendly, non-injection ophthalmic treatments.
  • Dermal Fillers (더말필러) Class III peptide-combination dermal filler medical device, CE certified under European standards, sold into the medical aesthetic market for facial volume and wrinkle indications.
  • Hair Fillers (헤어필러) Class III peptide-based hair filler medical device for hair restoration and scalp treatment applications, CE certified and sold into the medical aesthetic market.
  • Body Fillers (바디필러) Class III biomimetic peptide body filler medical device for body contouring and aesthetic treatments, positioned within the medical aesthetic device market.
  • Arthritis Injection (관절염 주사제) Peptide-based injectable medical device for arthritis treatment, used to expand Caregen's biomimetic peptide technology into the orthopedic and therapeutic medical device market.
  • Functional Food Supplements Peptide-based functional food and dietary supplement product line covering metabolic health, body fat management, blood sugar and cholesterol management, and sarcopenia response, sold to functional food brands and manufacturers as ingredients or finished products.
  • Cosmeceutical Solutions Integrated peptide-based cosmeceutical product line covering skin care, scalp care, hair care, and inner beauty applications, supplied to cosmetic and personal care brands and distribution partners globally.

Quantifiable outcome

  • CG-P5 FDA Phase 1 clinical trial completed for macular degeneration treatment
  • +2 more outcomes

Companies that use Caregen Co. Ltd

Customer profile

Segments4 records

Ideal customer profiles4 records

Caregen Co. Ltd technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Caregen Co. Ltd partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Global Distribution PartnerscoreChannel Partner/ Reseller/ DistributorCaregen operates global distribution networks to deliver its peptide-based solutions across food supplements, medical devices, cosmeceuticals, and pharmaceuticals to international markets. The company connects its technology and products directly to global markets through these distribution partnerships.
  • Partnership and Licensing PartnerscoreStrategic or Co-development PartnerCaregen offers partnership and licensing programs covering overview, types, value propositions, and global distribution aspects. Partners can access Caregen's peptide platform technology for applications in health functional foods, medical devices, cosmeceuticals, and pharmaceutical development including drug candidates like CG-P5.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Caregen Co. Ltd competitors and assessment

Company assessment

Market position

Strengths3 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Caregen Co. Ltd social profiles

Digital presence

Caregen Co. Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Caregen Co. Ltd leadership team

Management profile

Number of profiles

Caregen Co. Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Caregen Co. Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Caregen Co. Ltd

What does Caregen Co. Ltd do?

Caregen researches biological signaling mechanisms and develops biomimetic peptide-based solutions applied across four product categories: functional food supplements for metabolic health and body composition, Class III medical devices (dermal fillers, hair fillers, body fillers, and arthritis injectables), cosmeceuticals for skin, scalp, hair, and inner beauty, and peptide pharmaceuticals (CG-P5 for macular degeneration in eye drop form and CG-T1 for dry eye disease). The company operates its own peptide R&D centers and a dedicated Peptide Foundry for high-purity peptide manufacturing, and commercializes its platform through global distribution networks and partnership and licensing programs.

Is Caregen Co. Ltd a public or private company?

Caregen Co. Ltd is a public company. It is classified as public and is currently operating.

When was Caregen Co. Ltd founded?

Caregen Co. Ltd was founded in 2001. It employs 11 to 50 people.

Where is Caregen Co. Ltd based?

Caregen Co. Ltd is headquartered in Seoul, South Korea, in the Asia region.

How does Caregen Co. Ltd make money?

Five revenue lines are on record. Functional Food Supplements are the primary driver. The others are medical Devices, cosmeceuticals, pharmaceuticals - Licensing and partnership & Licensing.

Does Caregen Co. Ltd have an API?

No public API is recorded for Caregen Co. Ltd.

What industry is Caregen Co. Ltd in?

Caregen Co. Ltd's product category is Biotechnology — Biomimetic Peptide Ingredients and Products. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of AFAJAKAG, Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingCaregen chairman Chung Yong Ji lifts stake to 64.50% from 64.49% after open-market buyCaregen chairman Chung Yong Ji raised his stake to 64.50% from 64.49% after an open-market purchase of 5,000 shares on Sept. 29, 2026. The purchase averaged 40,000 per share, bringing his total holding to 34,647,606 shares.The future of tradingCaregen chairman Chung Yong Ji raises stake to 64.49% in on-market share buysCaregen chairman Chung Yong Ji raised his stake to 64.49% as of Sept. 28, 2026, holding 34,642,606 shares. The increase came from open-market purchases on Sept. 23 and 28 at average prices of 39,500 and 40,491 won.The future of tradingCaregen chairman Chung Yong Ji lifts stake to 64.48% after on-market share buysCaregen chairman Chung Yong Ji raised his stake to 64.48% after buying 7,458 shares on Sept. 22-23, 2026. The purchase cost KRW 294,222,300, funded with personal funds, bringing his total holding to 34,637,026 shares.Cosmetics BusinessBASF and Caregen ink synthetic cosmetic peptides supply agreementBASF signed an exclusive global supply agreement with Caregen for four synthetic cosmetic peptides with anti-ageing and anti-pigmentation properties. The peptides will be launched by BASF throughout 2021, expanding its dermocosmetics portfolio for Asia-based brands.ChosunbizKorglutide health supplement launches in Lebanon, faces challenges in advanced marketsCAREGEN launched Korglutide, a GLP-1-based oral weight-loss supplement, in Lebanon, claiming similar effects to injectables like Wegovy. The company plans to register it in Mexico by October and launch in November, but advanced markets may restrict it as a health functional food. Clinical trials showed 9.46% average weight loss in 100 patients.ChosunbizSouth Korea dominates hair loss cosmetic patents, filing 42.9% globallySouth Korea filed 42.9% of global hair loss cosmetic patents from 2002-2023, with 576 filings. Japan led with 272, the U.S. 231, and China 119. South Korean firms Caregen and Amorepacific led among companies.KoreatimesKorean cosmetics firms dominate global hair loss treatment marketKorean companies filed 576 of 1,344 global patent applications for hair loss cosmetics from 2002-2023, outpacing Japan, the U.S., China, and the EU. Caregen led with 115 applications, all in bioproducts, while AmorePacific led natural products with 40.Cosmetics BusinessBASF launches peptide ingredients series under Caregen partnershipBASF launched Peptovitae, a series of four patented peptides developed with Caregen, initially in Asia. The line includes Matrix, Bright, Derma, and Clear products, with expansion to other regions planned in 2022.